AMENDMENTS TO THE CLAIMS

Please amend the claims to read as follows:

1. *(Currently amended)* A method of treating a subject suffering from sepsis, comprising the steps of administering to said [[a]] subject an effective amount of a lipid or phospholipid moiety bonded to a ~~physiologically acceptable monomer, dimer, oligomer, or polymer~~ glycosaminoglycan, thereby treating the subject suffering from sepsis.

2. *(Withdrawn)* The method of claim 1, wherein said physiologically acceptable monomer is a salicylate, salicylic acid, aspirin, a monosaccharide, lactobionic acid, glucoronic acid, maltose, amino acid, glycine, carboxylic acid, acetic acid, butyric acid, dicarboxylic acid, glutaric acid, succinic acid, fatty acid, dodecanoic acid, didodecanoic acid, bile acid, cholic acid, cholesterylhemmisuccinate; or wherein the physiologically acceptable dimer or oligomer is a dipeptide, a disaccharide, a trisaccharide, an oligosaccharide, an oligopeptide, or a di- or trisaccharide monomer unit of glycosaminoglcans, hyaluronic acid, heparin, heparan sulfate, keratin, keratan sulfate, chondroitin, chondoitin sulfate,chondroitin-4-sulfate, chondoitin-6-sulfate, dermatin, dermatan sulfate, dextran, polygeline, alginate, hydroxyethyl starch, ethylene glycol, or carboxylated ethylene glycol; or wherein the physiologically acceptable polymer is a glycosaminoglycan, hyaluronic acid, heparin, heparan sulfate, chondroitin, chondroitin sulfate, keratin, keratan sulfate, dermatin, dermatan sulfate, carboxymethylcellulose, dextran, polygeline, alginate, hydroxyethyl starch, polyethylene glycol or polycarboxylated polyethylene glycol.

3. *(Currently amended)* The method of claim 1, wherein said glycosaminoglycan ~~physiologically acceptable polymer~~ is hyaluronic acid.

4. *(Currently amended)* The method of claim 1, wherein said glycosaminoglycan ~~physiologically acceptable polymer~~ is chondroitin sulfate.

5. *(Withdrawn)* The method of claim 1, wherein said lipid or phospholipid moiety is phosphatidic acid, an acyl glycerol, monoacylglycerol, diacylglycerol, triacylglycerol, sphingosine, sphingomyelin, ceramide, phosphatidylethanolamine, phosphatidylserine,

phosphatidylcholine, phosphatidylinositol, phosphatidylglycerol, or an ether or alkyl phospholipid derivative thereof.

6. *(Original)* The method of claim 1, wherein said phospholipid moiety is phosphatidylethanolamine.

7. *(Currently amended)* The method of claim 1, wherein ~~Use of a~~ said lipid or phospholipid moiety bonded to a ~~physiologically acceptable monomer, dimer, oligomer, or polymer~~ glycosaminoglycan is administered as part ~~in the preparation~~ of a pharmaceutical composition ~~for treating a subject afflicted with sepsis~~.

8. *-18. Cancelled.*

19. *(New)* The method of claim 6, where said phosphatidylethanolamine moiety is dimyristoyl phosphatidylethanolamine.

20. *(New)* The method of claim 1, wherein said phospholipid moiety is dipalmitoyl phosphatidylethanolamine and said glycosaminoglycan is hyaluronic acid.

21. *(New)* The method of claim 1, wherein said phospholipid moiety is dimyristoyl phosphatidylethanolamine and said glycosaminoglycan is hyaluronic acid.

22. *(New)* The method of claim 1, wherein said phospholipid moiety is dipalmitoyl phosphatidylethanolamine and said glycosaminoglycan is chondroitin sulfate.